{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124576","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.432910+00:00","generated_at":"2026-05-30T02:04:12.463729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BridgeBio posts Q3 net loss of $162M; acoramidis PDUFA set for Nov 29, 2024","bullets":["Net loss per share of $0.86; revenue $2.7M vs $4.1M YoY; operating expenses $194.5M.","Cash, equivalents, and short-term restricted cash $405.7M; expects $500M milestone from acoramidis upon FDA approval.","FDA accepted acoramidis NDA; PDUFA date November 29, 2024; 42-month OLE data to be presented at AHA.","FDA granted Breakthrough Therapy Designation to oral infigratinib for achondroplasia.","Phase 3 FORTIFY trial for LGMD2I/R9 enrollment completed; interim analysis expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124576","json":"https://secwatch.observer/filing/0000950170-24-124576.json","markdown":"https://secwatch.observer/filing/0000950170-24-124576.md","text":"https://secwatch.observer/filing/0000950170-24-124576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/0000950170-24-124576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:04:12.463729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}